Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

University of Waterloo

$60,000.00

Self-assembling peptides for anticancer drug delivery

EF 2009-10

Résumé
Cancer is the second leading cause of death in the developed countries only after heart disease, causing over 70,000 fatalities each year in Canada alone. Presently about 50% cancer patients can be cured, with chemotherapy contributing to cure in 10-15% of the patients. All clinical use of the anticancer drugs involves weighing of benefits against unwanted side-effects. To overcome this bottleneck, targeted drug delivery has been heavily pursued. A new and effective delivery strategy has recently emerged when peptides (small proteins) are used in the design of drug delivery systems. In this application, we propose to develop effective therapeutic delivery technologies using a newly-discovered class of peptides--ionic-complementary, amphiphilic, self-assembling peptides. These peptides not only possess specific drug targeting functions but also derive surfactant-like characteristics, and hence self-assembly capability, from their unique molecular arrangements (amino acid sequences). Recently, we have demonstrated that these peptides can enclose a model drug and further deliver it into model cells in a controlled manner. Preliminary animal studies have shown our peptide-assisted delivery systems to be safe and efficacious. The three objectives in the current proposal are: a) to develop and optimize formulation of anticancer drugs with self-assembling peptides, b) to demonstrate peptide-mediated delivery of anticancer drugs on biological cells, and c) to evaluate such delivery systems with a mouse tumor model. A success of the proposed research will generate new anticancer drug formulations for chemotherapy, contributing to the health care, cancer treatment in particular, of Canadians. To facilitate the timely translation of our research results into health benefits, appropriate industrial partnership has been established for joint research and development, and eventual product commercialization.
Programme
Collaborative Research and Development Grants
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
373355-2008
Name nom
Chen, Pu
Department département
Chemical Engineering
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
60000
Program id
CRDPJ
Program nane en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
1900
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical engineering
Research subject fr
Génie biomédical
Partie
1
Nb partie
3
Application title
Self-assembling peptides for anticancer drug delivery
Keyword
NA
Application summary
Cancer is the second leading cause of death in the developed countries only after heart disease, causing over 70,000 fatalities each year in Canada alone. Presently about 50% cancer patients can be cured, with chemotherapy contributing to cure in 10-15% of the patients. All clinical use of the anticancer drugs involves weighing of benefits against unwanted side-effects. To overcome this bottleneck, targeted drug delivery has been heavily pursued. A new and effective delivery strategy has recently emerged when peptides (small proteins) are used in the design of drug delivery systems. In this application, we propose to develop effective therapeutic delivery technologies using a newly-discovered class of peptides--ionic-complementary, amphiphilic, self-assembling peptides. These peptides not only possess specific drug targeting functions but also derive surfactant-like characteristics, and hence self-assembly capability, from their unique molecular arrangements (amino acid sequences). Recently, we have demonstrated that these peptides can enclose a model drug and further deliver it into model cells in a controlled manner. Preliminary animal studies have shown our peptide-assisted delivery systems to be safe and efficacious. The three objectives in the current proposal are: a) to develop and optimize formulation of anticancer drugs with self-assembling peptides, b) to demonstrate peptide-mediated delivery of anticancer drugs on biological cells, and c) to evaluate such delivery systems with a mouse tumor model. A success of the proposed research will generate new anticancer drug formulations for chemotherapy, contributing to the health care, cancer treatment in particular, of Canadians. To facilitate the timely translation of our research results into health benefits, appropriate industrial partnership has been established for joint research and development, and eventual product commercialization.